Description
This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment:
- Nucleoside Analogs
- Protease Inhibitors
- Other Misc. Antivirals
The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an
- An overview
- Description of products on the market
- Description of products in development
- Market estimates and forecasts through 2009
- Market segmentation by infection type
- Market segmentation by geographic region
- Market share of leading suppliers
- Market share of leading products
The report also includes statistical (epidemiologic and demographic) information for viral infections by type worldwide, with special emphasis on the United States and describes the major clinical, business, and regulatory trends shaping the global and domestic markets.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Introduction to Viruses
- Examples of Pathogenic Viruses
- Virus Function and Life History
- Replication in DNA Viruses
- Replication of RNA Viruses
- Replication in Retroviruses
- Host Defenses Against Viruses
- Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
- HIV and AIDS
- Demographics and Epidemiology
- Cytomegalovirus
- Hepatitis B Virus
- Hepatitis C Virus (HCV)
- Herpes
- Human Immunodeficiency Virus (HIV)
- Human Papillomavirus (HPV)
- Influenza
- Respiratory Syncytial Virus (RSV)
- Population Demographics
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Overview
- Description of Products
- Nucleoside Reverse Transcriptase Inhibitors
- Zidovudine (Retrovir, GlaxoSmithKline)
- Didanosine (Videx, Bristol-Myers Squibb)
- Zalcitabine (Hivid, Roche)
- Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
- Stavudine (Zerit, Bristol-Myers Squibb)
- Abacavir (Ziagen, GlaxoSmithKline)
- Nucleotide Analogue Reverse Transcriptase Inhibitors
- Tenofovir (Viread, Gilead Sciences)
- Adefovir dipivoxil (Hepsera, Gilead Sciences)
- Combination Nucleoside Reverse Transcriptase Inhibitors
- Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
- Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
- Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nevirapine (Viramune, Boehringer Ingelheim)
- Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
- Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
- Emtricitabine (Emtriva, Gilead Sciences)
- DNA Polymerase Inhibitors
- Acyclovir (Zovirax, GlaxoSmithKline)
- Valacyclovir (Valtrex, GlaxoSmithKline)
- Famciclovir (Famvir, Novartis)
- Penciclovir (Denavir, Novartis)
- Ganciclovir (Cytovene, Roche)
- Ribavirin (Virazole, ICN Pharmaceuticals)
- Foscarnet (Foscavir, AstraZeneca)
- Valganciclovir (Valcyte, Hoffman-LaRoche)
- Cidofovir (Vistide, Gilead Sciences)
- Research and Development
- Baraclude
- Truvada
- Telbivudine
- Viramidine
- Capravirine
- Elvucitabine
- Epzicom
- Etravirine (TMC125)
- GW5634
- MIV 150
- Pradefovir
- Reverset
- TMC278
- Valopicitabine
- Valtorcitabine
- BILR 355
- Calanolide A
- DPC 961 and DPC 963
- GW8248
- MCC-478
- MIV-310
- Market Size and Growth
- Competitive Analysis
Chapter Four: Protease Inhibitors
- Overview
- Description of Products
- Single Agents
- Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
- Nelfinavir (Viracept, Agouron Pharmaceuticals)
- Indinavir (Crixivan, Merck)
- Ritonavir (Norvir, Abbott Laboratories)
- Amprenavir (Agenerase, GlaxoSmithKline
- Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
- Atazanavir (Reyataz, Bristol-Myers Squibb)
- Combination Protease Inhibitors
- Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
- Research and Development
- Tipranavir (PNU-140690)
- GW640385 (VX-385)
- TMC-114
- BMS232632
- RO033-4649
- VX-950
- Market Size and Growth
- Competitive Analysis
Chapter Five: Other Antivirals
- Overview
- Description of Products
- Aldara
- CytoGam
- Flumadine
- Fuzeon
- Infergen
- Pegasys
- Pegasys + Copegus
- Rebetol, Rebetron
- Relenza
- RespiGam
- Symmetrel
- Synagis
- Tamiflu
- Vistide
- Research and Development
- Attachment and Fusion Inhibitors
- Gene Therapies
- Integrase Inhibitors
- Maturation Inhibitors
- Zinc Finger Inhibitors
- Antisense Drugs
- Cytokines
- Other
- Market Size and Growth
- Competitive Analysis
Chapter Six: Issues and Trends
- Introduction
- Antiviral Drug Resistance
- HIV Drug Cost Controversy
- Antiretroviral Treatment Regimens
- HIV and Women
- Global Surveillance
- Biochemical Prevention and Treatment of Viral Infections
- New Treatment for Hepatitis C
- Costs and Funding of HIV Treatment
- Access to HIV/AIDS Treatment
Chapter Seven: Total Market Size and Forecast
- Overview
- Total Market Size and Forecast
chapter Eight: Corporate Profiles
- Introduction
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline
- MedImmune, Inc.
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Roche
- Schering-Plough Corporation
APPENDIX: Company Names and Addresses
List of Exhibits
Chapter One: Executive Summary
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
Chapter Two: Introduction
- Table 2-1: Host Cell Receptors
- Table 2-1: Estimated World and U.S. Incidence of Viral Infections
- Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
- Table 2-2: World Population by Selected Geographical Region, 2004-2050
- Figure 2-2: World Population by Selected Geographical Region, 2003-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2004
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2004
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
- Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
- Table 3-3: Currently Available DNA Polymerase Inhibitors
- Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
- Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
- Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
- Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
- Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
- Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
- Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
- Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004
Chapter Four: Protease Inhibitors
- Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
- Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 4-3: The Market for Protease Inhibitors 2002-2009
- Figure 4-1: Protease Inhibitor Market 2002-2009
- Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
- Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
- Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004
Chapter Five: Other Antivirals
- Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
- Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 5-3: The Market for Other Antivirals 2002-2009
- Figure 5-1: The Market for Other Antivirals 2002-2009
- Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
- Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
- Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
- Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
- Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
- Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
- Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004
Chapter Six: Issues and Trends
- Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
- Table 6-2: Funding for HIV/AIDS
- Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
- Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World
Chapter Seven: Total Market Size and Forecast
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
- Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
- Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009
